---
title: "SYNERGY: The raw material drug Amlodipine Besylate has passed the GMP compliance inspection"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/252990104.md"
description: "SYNERGY announced that its raw material drug, Mesalazine Potassium, has passed the GMP compliance inspection, which is beneficial for the company to expand the sales of its products in the domestic market, forming a good pattern of simultaneous sales in both domestic and foreign markets. Mesalazine Potassium is suitable for the treatment of adult primary hypertension"
datetime: "2025-08-14T08:22:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/252990104.md)
  - [en](https://longbridge.com/en/news/252990104.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/252990104.md)
generator: "portal-rs"
---

# SYNERGY: The raw material drug Amlodipine Besylate has passed the GMP compliance inspection

SYNERGY announced that the company's raw material drug Mesalazine Potassium has passed the drug GMP compliance inspection, which is beneficial for the company to expand the product's sales in the domestic market, forming a good pattern of simultaneous sales in both domestic and foreign markets. Mesalazine Potassium is suitable for the treatment of adult primary hypertension

### Related Stocks

- [300636.CN](https://longbridge.com/en/quote/300636.CN.md)

## Related News & Research

- [Chinese Pharma Companies Plan Hong Kong Listings](https://longbridge.com/en/news/297979501.md)
- [Alembic Pharmaceuticals Sets Up Wholly Owned Subsidiary in Dubai to Drive Global Expansion](https://longbridge.com/en/news/298223880.md)
- [11:06 ETStem Cells Market to Reach US$ 32.57 Bn by 2031, Growing at 11.5% CAGR: Wissen Research](https://longbridge.com/en/news/298223578.md)
- [RUBBER-Japan rubber futures ease as oil prices slip, yen firms](https://longbridge.com/en/news/297846575.md)
- [DAZN partners with SENSHI to stream kickboxing events worldwide for free](https://longbridge.com/en/news/298082089.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**